George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.50
Ask: 18.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.857%)
Open: 17.75
High: 17.75
Low: 17.75
Prev. Close: 17.75
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

OptiBiotix obtains BRC accreditation

5 Jan 2022 07:00

RNS Number : 4249X
OptiBiotix Health PLC
05 January 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

OptiBiotix obtains British Retail Consortium accreditation

One of the leading international food safety standards

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing unique science and human study-based compounds that modulate the microbiome to address metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and to support healthy aging has achieved British Retail Consortium ('BRC') accreditation.

 

BRC was the first standard to meet the Global Food Safety Initiative ('GFSI') benchmark, which means it is accepted by many of the world's biggest retailers, such as Tesco and Walmart. The certification ensures customers have confidence in OptiBiotix's products and it allows the Company to do business with those retailers, manufacturers, ingredients companies and food service organisations who specify certification as part of their approval process (most large retailers and their suppliers). It incorporates food safety management systems and internationally accepted best practice to ensure the safety and quality of products and in doing so reduces the risk of recalls.

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased to announce our BRC accreditation which supports our commercial strategy of selling final product solutions to partners in the retail channel containing our science backed pro and prebiotic ingredients. I am particularly proud of our team which achieved this accreditation in a relatively short period of time."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASSUFWLEESEFF
Date   Source Headline
7th May 20197:00 amRNSLicense agreement for LPLDL®
2nd May 20197:00 amRNSInvestor evening
1st May 20197:00 amRNSSlimBiome launch to EU market at Vitafoods Europe
29th Apr 20197:00 amRNSFinal Results
24th Apr 20197:00 amRNSSlimBiome® Medical launches in UK market
11th Apr 20197:00 amRNSSlimBiome® receives approval from FSSAI in India
9th Apr 20197:00 amRNSSlimBiome® Medical agreement for Bulgaria
27th Mar 20193:18 pmRNSGrant of Options
27th Mar 20197:43 amRNSSweetBiotix®: Scientific and commercial update
27th Mar 20197:00 amRNSSweetBiotix®: Scientific and commercial update
25th Mar 201911:00 amRNSPrice Monitoring Extension
20th Mar 20197:00 amRNSExclusive distribution agreement for SlimBiome®
15th Mar 20197:00 amRNSExtension of term and territories for LPLDL®
13th Mar 20193:42 pmRNSExercise of Warrants
21st Feb 20197:00 amRNSLPLDL® determined GRAS by an Expert Panel in US
20th Feb 20197:00 amRNSPresentations at ProBiota - 2019
13th Feb 20197:00 amRNSTrading Statement
11th Feb 20197:00 amRNSDistribution agreement for LPLDL® in Japan
7th Feb 20197:00 amRNSSupply agreement for LPLDL® in the Baltic States
18th Jan 20191:56 pmRNSExercise of Warrants
11th Jan 20197:00 amRNSDirector Appointment
9th Jan 20197:00 amRNSDistribution agreement for CholBiome
7th Jan 20197:00 amRNSManufacturing agreement for SlimBiome®
17th Dec 20187:00 amRNSDirectorate Change
14th Dec 20187:00 amRNSIssue of Convertible Loan Notes by ProBiotix
5th Dec 20182:58 pmRNSHolding(s) in Company
4th Dec 20187:00 amRNSSlImBiome® Medical agreement for Greece and Cyprus
29th Nov 20187:00 amRNSSlimBiome Medical manufacturing agreement
27th Nov 20187:00 amRNSSlimBiome® granted medical device status & CE mark
22nd Nov 20187:00 amRNSCholBiome® agreement for Greece and Cyprus
11th Oct 20187:00 amRNSDirector's Dealing
9th Oct 20187:00 amRNSLPLDL® US manufacturing and supply agreement
8th Oct 20187:00 amRNSExercise of Options & Director's Dealing
3rd Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
1st Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
26th Sep 20187:00 amRNSDistribution agreement for CholBiome®
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 20187:00 amRNSFormation of ProBiotix Health Limited
10th Sep 20187:00 amRNSDirector Appointment
10th Sep 20187:00 amRNSLicence agreement with Bened Biomedical
10th Sep 20187:00 amRNSExercise of Warrants and Issue of Equity
4th Sep 20187:00 amRNSOptiBiotix signs US pharmaceutical deal
30th Aug 20187:00 amRNSHalf-year Report
6th Aug 20187:00 amRNSProposed directorate change
31st Jul 201810:04 amRNSDirector's dealing
17th Jul 20187:00 amRNSGrant of Options
12th Jul 20187:00 amRNSDirector's dealing
6th Jul 201812:00 pmRNSHolding(s) in Company
4th Jul 20182:07 pmRNSResult of AGM
4th Jul 20187:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.